Jen-Chieh Chuang

Dr. Jen-Chieh Chuang is a translational medicine and Biomarker leader driving innovation in liver disease therapeutics, currently serving as Global Program Lead and Translational Medicine & Biomarker Lead for Liver Diseases at Takeda. With a robust background in fibrosis research and drug development, he spearheads strategies to bridge biomarker discovery with clinical applications.
Prior to Takeda, Dr. Chuang held key roles across academia and industry, including Senior Research Scientist II at Gilead Sciences, where he contributed to advancing antifibrotic therapies in MASH and PSC, and Scientist at Reata Pharmaceuticals, focusing on novel mechanisms in metabolic and fibrotic kidney diseases. His academic foundation includes postdoctoral training at UT Southwestern Medical Center, where he later served as Assistant Instructor at the Children’s Medical Center Research Institute, deepening his expertise in liver pathophysiology and regenerative medicine. Dr. Chuang earned his PhD in Integrative Biology from UT Southwestern, where his research illuminated molecular pathways underlying metabolic diseases including obesity, diabetes, and fibrotic liver & kidney diseases. A cross-disciplinary scientist, he combines expertise in biomarker discovery & development, translational models, and clinical program leadership to accelerate therapies for liver fibrosis and related disorders.